Not bad considering... My estimate was between 40 and 60 million so i'm hppy with that. Remember AH was not experiencing any growth so 1 to 2 times sales is a reasonable valuation. Had BNC pursued a growth strategy fo AH a few years ago then we would have seen the 3 to 10 times. But they didn't so....we'll just watch Vetoquinnol enjoy that gain as did the group that bought Bioniche Pharma for $38 m . Didn't they sell it for $ 555m 4 years later?
Bioniche is not in business to be in business!
Do you suppose current IR department will go along to France as part of the deal? Then, the next part of my fantasy - they hire https:///wwww.blowyourownhorn.com and get Ottawa on side re. ecoli. I think farmers might reconsider, beef sales have fallen off, consumers have lost a lot of faith in the industry and in Health Canada.
How's this for a headline:
"Econiche may not just save lives it could theoretically save an entire industry."
Onward...
I am a bit curious about a statement...In the release Doc Berendt stated: "Our goal..., and the addition of another oncology asset to our development pipeline."
What addition , did i miss something????
Will they bring on all other mcc technology, colon, breast etc....That could be very significant.
Reminder of the power of MCC platform:
About Mycobacterial Cell Wall-DNA Complex (MCC)
Mycobacterial Cell Wall-DNA Complex (MCC) is a patented cell wall composition isolated from Mycobacterium phlei. MCC is a bifunctional agent with a direct effect on cancer cells (chemotherapeutic-like activity) as well as a stimulatory activity on immune effector cells such as macrophages and monocytes. MCC is a platform technology, offering opportunities to develop a range of oncology and immune stimulatory applications in both humans and animals.